The Effect of Pentoxifylline on Passive Avoidance Learning and Expression of Tumor Necrosis Factor-Alpha and Caspase-3 in the Rat Hippocampus Following Lipopolysaccharide-Induced Inflammation

Akbari, Zahra; Reisi, Parham; Torkaman-Boutorabi, Anahita; Farahmandfar, Maryam

The Effect of Pentoxifylline on Passive Avoidance Learning and Expression of Tumor Necrosis Factor-Alpha and Caspase-3 in the Rat Hippocampus Following Lipopolysaccharide-Induced Inflammation

Authors

¹ Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine; International Campuses, Tehran University of Medical Sciences Tehran, Iran

² Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

³ Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

⁴ Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine; Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Peripheral inflammation is effective in the development of neurodegenerative diseases. Pentoxifylline (PTX) has an inhibitory effect on inflammatory cytokines; therefore, we aimed to evaluate the effect of PTX on passive avoidance learning and the expression of tumor necrosis factor-alpha (TNF-α) and caspase-3 in the rat hippocampus, following systemic lipopolysaccharide (LPS) injection. Materials and Methods: Male Wistar rats were randomly divided into five groups: control, LPS, and LPS + PTX, receiving doses of 10, 25, and 50 mg/kg of PTX, respectively. The animals received daily injections of PTX (i.p.) 1 week before and 2 weeks after the LPS injection (5 mg/kg; i.p.). Learning and memory were evaluated by passive avoidance learning. Then, the expression of the associated genes was measured in the hippocampus. Results: The results showed that the peripheral LPS injection had no significant effect on learning and memory. PTX only with a dose of 10 mg/kg shows an improvement (P < 0.05). Results from reverse transcription polymerase chain reaction showed that LPS had no significant effect on the expression of caspase-3 and TNF-α. PTX with a dose of 10 mg/kg decreased the caspase-3 expression in the LPS + PTX group (P < 0.001), but the expression of both genes increased, using other concentrations. Conclusions: Findings showed that systemic application of LPS after 2 weeks had no effect on learning and memory and the expression of inflammatory genes in the hippocampus, but PTX led to an increase in the expression of these genes, which could be due to its direct effects or possible exacerbation of LPS effects.

Keywords

References

1.	Ferrari CC, Tarelli R. Parkinson's disease and systemic inflammation. Parkinsons Dis 2011;2011:436813.
2.	Saavedra JM. Angiotensin II AT (1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond) 2012;123:567-90.
3.	Saavedra JM. Angiotensin II AT (1) receptor blockers ameliorate inflammatory stress: A beneficial effect for the treatment of brain disorders. Cell Mol Neurobiol 2012;32:667-81.
4.	Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
5.	Sankowski R, Mader S, Valdés-Ferrer SI. Systemic inflammation and the brain: Novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci 2015;9:28.
6.	Holmes C. Review: Systemic inflammation and Alzheimer's disease. Neuropathol Appl Neurobiol 2013;39:51-68.
7.	Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon RM, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 2009;65:304-12.
8.	Assimakopoulos SF, Thomopoulos KC, Labropoulou-Karatza C. Pentoxifylline: A first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J Gastroenterol 2009;15:3194-5.
9.	Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE) 4 inhibitors: Anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997;18:164-71.
10.	Zhu DJ, Xia B, Bi Q, Zhang SJ, Qiu BS, Zhao C. Functional protection of pentoxifylline against spinal cord ischemia/reperfusion injury in rabbits: Necrosis and apoptosis effects. Chin Med J (Engl) 2008;121:2444-9.
11.	Li R, Tong J, Tan Y, Zhu S, Yang J, Ji M. Low molecular weight heparin prevents lipopolysaccharide induced-hippocampus-dependent cognitive impairments in mice. Int J Clin Exp Pathol 2015;8:8881-91.
12.	Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007;55:453-62.
13.	Azadbakht AA, Radahmadi M, Javanmard SH, Reisi P. The effects of doxepin on stress-induced learning, memory impairments, and TNF-α level in the rat hippocampus. Res Pharm Sci 2015;10:460-5.
14.	Reisi P, Eidelkhani N, Rafiee L, Kazemi M, Radahmadi M, Alaei H. Effects of doxepin on gene expressions of Bcl-2 family, TNF-α, MAP kinase 14, and akt1 in the hippocampus of rats exposed to stress. Res Pharm Sci 2017;12:15-20.
15.	Rezayani S, Farazmandfar T. Association assessment of platelet derived growth factor B gene polymorphism and its expression status with susceptibility to coronary artery disease. Egypt J Med Hum Genet 2017;18:359-63.
16.	Janbabai G, Oladi Z, Farazmandfar T, Taghvaei T, Naghshvar F. The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative real-time PCR. J Cancer Res Clin Oncol 2015;141:1945-52.
17.	Rossol M, Heine H, Meusch U, Quandt D, Klein C, Sweet MJ, et al. LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol 2011;31:379-446.
18.	Verma S, Nakaoke R, Dohgu S, Banks WA. Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. Brain Behav Immun 2006;20:449-55.
19.	Zetterström M, Sundgren-Andersson AK, Ostlund P, Bartfai T. Delineation of the proinflammatory cytokine cascade in fever induction. Ann N Y Acad Sci 1998;856:48-52.
20.	Erickson MA, Banks WA. Cytokine and chemokine responses in serum and brain after single and repeated injections of lipopolysaccharide: Multiplex quantification with path analysis. Brain Behav Immun 2011;25:1637-48.
21.	Biesmans S, Meert TF, Bouwknecht JA, Acton PD, Davoodi N, De Haes P, et al. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm 2013;2013:271359.
22.	Roth J, Harré EM, Rummel C, Gerstberger R, Hübschle T. Signaling the brain in systemic inflammation: Role of sensory circumventricular organs. Front Biosci 2004;9:290-300.
23.	Saavedra JM, Sánchez-Lemus E, Benicky J. Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology 2011;36:1-8.
24.	González H, Elgueta D, Montoya A, Pacheco R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol 2014;274:1-3.
25.	Welser-Alves JV, Milner R. Microglia are the major source of TNF-α and TGF-β1 in postnatal glial cultures; regulation by cytokines, lipopolysaccharide, and vitronectin. Neurochem Int 2013;63:47-53.
26.	Honardoost M, Soleimanjahi H, Rajaei F. Apoptosis: Programmed cell death. JQUMS 2013;17:48-57.
27.	Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001;20:2122-33.
28.	Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther 2001;92:57-70.
29.	Steller H. Mechanisms and genes of cellular suicide. Science 1995;267:1445-9.
30.	Shaw KN, Commins S, O'Mara SM. Lipopolysaccharide causes deficits in spatial learning in the watermaze but not in BDNF expression in the rat dentate gyrus. Behav Brain Res 2001;124:47-54.
31.	Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008;5:37.
32.	Pugh CR, Kumagawa K, Fleshner M, Watkins LR, Maier SF, Rudy JW. Selective effects of peripheral lipopolysaccharide administration on contextual and auditory-cue fear conditioning. Brain Behav Immun 1998;12:212-29.
33.	Arai K, Matsuki N, Ikegaya Y, Nishiyama N. Deterioration of spatial learning performances in lipopolysaccharide-treated mice. Jpn J Pharmacol 2001;87:195-201.
34.	Thomson LM, Sutherland RJ. Systemic administration of lipopolysaccharide and interleukin-1beta have different effects on memory consolidation. Brain Res Bull 2005;67:24-9.
35.	Cunningham C, Sanderson DJ. Malaise in the water maze: Untangling the effects of LPS and IL-1beta on learning and memory. Brain Behav Immun 2008;22:1117-27.
36.	Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011;25:181-213.
37.	Czerniawski J, Miyashita T, Lewandowski G, Guzowski JF. Systemic lipopolysaccharide administration impairs retrieval of context-object discrimination, but not spatial, memory: Evidence for selective disruption of specific hippocampus-dependent memory functions during acute neuroinflammation. Brain Behav Immun 2015;44:159-66.
38.	Panahi Khezri N, Nadia Sharifi Z, Shafaroodi H, Ansarian G, Movassaghi S. The effect of pentoxifylline on global ischemia/reperfusion induced spatial memory impairment in estrous phase of female wistar rat. Med Sci J Islamic Azad Univ Tehran Med Branch 2014;24:14-21.

Advanced Biomedical Research